It is worth considering and testing whether simultaneously targeting myeloid NF-κB2 and RelA, and perhaps also tumor RelA, shows better efficacy, since lung cancer suppression by myeloid RelA and NF-κB2 deletions involves different mechanisms, whereas intrinsic RelA promotes lung cancer as well (5, 12, 14). Here, NFKB2 is linked to lung cancer.